1. Introduction {#sec0005}
===============

Cholangiolocellular carcinoma (CoCC) is a rare type of liver cancer [@bib0005], [@bib0010], and was first reported by Steiner and Higginson in 1959 [@bib0005]. CoCC is derived from the Canals of Hering, or cholangioles, where hepatic progenitor cells (HPCs) are located [@bib0015]. HPCs have the potential to differentiate into hepatocytes and cholangiocytes [@bib0020], and expression of the HPC markers CD56, CD13, and epithelial cell adhesion molecule (EpCAM) are characteristic of CoCC [@bib0025].

It is difficult to diagnose CoCC preoperatively without histopathological anaysis; its radiological attributes are very similar to those of cholangiocellular carcinoma (CCC) and malignant lymphoma, which are characterized by tumor enhancement patterns and a specific shape on contrast-enhanced computed tomography (CT) [@bib0030]. Vascular penetration into the tumor, with no capsule present, is one of the notable characteristics of CoCC [@bib0035]. The disease has a post-curative surgery prognosis that lies between hepatocellular carcinoma (HCC) and CCC, in terms of favorable outcomes [@bib0040], [@bib0045].

We present a patient with CoCC who underwent curative surgery, although multiple liver recurrences were observed 6 months later. We also conduct a literature review on CoCCs. This work has been reported in line with the SCARE criteria [@bib0050].

2. Presentation of case {#sec0010}
=======================

The patient was a 79-year-old woman with hypertension; she had no relevant medical history and did not abuse alcohol. Elevated carbohydrate antigen 19-9 (CA19-9) was noted during an annual medical examination, and she was admitted to the Department of Surgery at our institution. Her physical examination was normal; however, her levels of tumor markers were as follows: CA19-9, 370 U/mL (normal, \<37.0 U/mL); carcinoembryonic antigen, 1.6 ng/mL (normal, \<5.5 ng/mL); alfa-fetoprotein, 2.2 ng/mL (normal, \<10.0 ng/mL); and protein induced vitamin K absence or antagonists-II, 20 mAU/mL (normal, \<40 mAU/mL). Hepatitis virus markers were all negative. Her laboratory data indicated a Child-Pugh A classification. Contrast-enhanced CT revealed a tumor located in segment 4 measuring 60 mm (at most) with an unclear border. In early-phase imaging, the tumor showed enhancement at the tumor periphery; this was prolonged on late-phase imaging ([Fig. 1](#fig0005){ref-type="fig"}). With magnetic resonance imaging (MRI), the tumor showed low and high intensities on T1-and T2-weighted images, respectively. This enhancement was washed out in the hepatocellular phase. Interestingly, the hepatic artery was observed penetrating the tumor on both CT and MRI. The patient's preoperative diagnosis was CCC following which left hepatectomy and cholecystectomy were performed. The duration of the surgery was 262 min, and the bleeding volume was 200 mL. Macroscopically, the tumor in segment 4 of the liver was a 60 × 55 × 50 mm well-defined yellowish-white lesion. Histological examination revealed that the proliferating tumor cells replaced the surrounding normal tissue, and were composed of antler-like and anastomosing patterns with abundant fibrous stroma. There was no invasion into the vessels or lymph ducts. Immunohistochemical examination revealed positive expression of cytokeratin (CK) 7, CK19, and EpCAM ([Fig. 2](#fig0010){ref-type="fig"}). Hence, the final diagnosis was CoCC.

The patient was discharged on postoperative day 12 without any complications, and she was administered adjuvant chemotherapy with S-1. However, follow-up CT 6 months after surgery showed multiple liver metastases; therefore, the patients is now receiving systematic chemotherapy with gemcitabine.

3. Discussion {#sec0015}
=============

CoCC comprises mixed HCC and CCC components, and is categorized as a subtype of CCC based on World Health Organization (WHO) guidelines. The frequency of CoCC occurrence is 0.6--1% among primary liver tumors [@bib0005], [@bib0010]. Recent histological and immunohistochemical findings have indicated that CoCC are derived from HPCs, which are liver-specific stem cells that can differentiate into hepatocytes and cholangiocytes [@bib0015]. Previous studies also showed that most patients with CoCC were infected with hepatitis B or C viruses, or else abused alcohol; inflammation caused by the viral infection is thought to be a risk factor for CoCC [@bib0015], [@bib0040].

Characteristic radiological findings for CoCC are patchy enhancement patterns in the arterial phase; these enhanced effects are delayed in the equilibrium phase because of the abundant fibrous stroma of the tumor [@bib0030], [@bib0055], [@bib0060]. Some reports have described the imaging findings of CoCC to be very similar to those of CCC or HCC [@bib0010], [@bib0065]. HCCs commonly show rapid homogeneous enhancement of the tumor that quickly washes out in the late phase [@bib0070]. On the other hand, CCC is characterized by a thin and mild peripheral enhancement on early-phase images that is due to an abundant fibrous stroma [@bib0075]. Previous studies demonstrated that the presence of a non-obstructed vessel within the tumor (without a capsule) as well as the absence of intratumoral necrosis were particularly characteristic of CoCC [@bib0035], [@bib0065]. The mechanism of vessel penetration into a tumor was shown to have a replacing growth pattern rather than a compressive one [@bib0060]. Portal vein penetration into the tumor has been reported [@bib0060], and is commonly detected in malignant lymphoma or CCC [@bib0065]. On the other hand, the penetration of the hepatic artery into the tumor has not been previously reported. The difference between the feeding and penetrating arteries on CT is that the feeding artery appears to be involved with the tumor, and radially narrows so that it is undetectable on CT when it is in close proximity to the lesion. However, a penetrating artery persists after passing through the tumor and can be traced on CT. Hepatic artery penetration may therefore be an important finding in CoCC, and may represent a unique tumor growth pattern.

Pathological and immunohistological examinations are important for the diagnosis of CoCC. According to the WHO classification, the histologic features of CoCC include admixtures of small monotonous glands, antler-like or anastomosing patterns with abundant fibrous stroma, and cuboidal tumor cell that are smaller in size than normal hepatocytes. Immunohistochemical examination is also useful for the diagnosis of CoCC; because they were derived from HPCs, these tumor cells are positive for CD155, CD44, and EpCAM . Some studies reported that the biliary markers CK9 and CK19 were expressed in CoCCs [@bib0025]; the tumor in our case showed positivity for EpCAM, CK7, and CK19.

A list of reported patients with CoCC who underwent resection is shown in [Table 1](#tbl0005){ref-type="table"} [@bib0030], [@bib0055], [@bib0080], [@bib0085], [@bib0090], [@bib0095], [@bib0100], [@bib0105]. CoCC exhibits less invasion to the portal vein as well as a lower number of intrahepatic metastases than CCC [@bib0040]. Therefore, patients with CoCC survived longer after surgery than those with CCC [@bib0015], [@bib0040]. Tomioku et al. reported a patient who underwent repeated hepatectomy for recurrent intrahepatic CoCC [@bib0030]; hence, patients with solitary and metachronous liver recurrence may be candidates for curative resection. In fact, curative resection is the first choice for patients with CoCC. The prognosis and recurrence rates of CoCC are also unclear, although a maximal tumor size of \>40 mm was reported to be an independent risk factor for recurrence [@bib0015]. Despite receiving adjuvant chemotherapy, our patient, whose tumor had a maximum diameter of 60 mm, experienced early recurrence. The effect of chemotherapy in patients with CoCC remains unclear; further investigations are required to determine effective adjuvant chemotherapy regimens for this disease.

4. Conclusion {#sec0020}
=============

We reported a case of CoCC in a normal liver that exhibited penetration by the hepatic artery. Multiple liver recurrences occurred even after curative surgery. The tumor size, as well as the unique growth pattern that involved hepatic artery penetration through the tumor, appeared to be risk factors for recurrence.
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![Preoperative computed tomography. (A) The tumor in the left hepatic lobe showed enhancement from its periphery, with penetration of the hepatic artery and the dilatation of the peripheral biliary duct in the arterial phase (white arrow). Liver cysts were observed in segments 5 (black arrow). (B) Tumor enhancement was prolonged in the equilibrium phase.](gr1){#fig0005}

![Immunohistochemical findings of the tumor. (A) Hematoxylin and eosin staining: The tumor was composed of small glands showing antler-like and anastomosing patterns with abundant fibrous stroma. The tumor was positive for cytokeratin (CK) 7 (B), CK19 (C), and epithelial cell adhesion molecule (D).](gr2){#fig0010}

###### 

Reported clinicopathological variables of patients with CoCC following curative surgery.

Table 1

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author         Age   Sex   Etiology   CEA\     CA19-9\   Tumor location   Maximal tumor size\   Surgery                                         CK7/19   EpCAM   Postoperative therapy    Prognosis
                                        (ng/L)   (U/mL)                     (mm)                                                                                                            
  -------------- ----- ----- ---------- -------- --------- ---------------- --------------------- ----------------------------------------------- -------- ------- ------------------------ ----------------------------------------------------
  Matsuda        70    M     HCV        Normal   Normal    S7               22                    Medial and posterior segmentectomy without LD   ND/+     (−)     ND                       Alive for 30 months without recurrence

  Kanamoto       71    M     HCV        Normal   Normal    Right lobe       15                    Partial hepatectomy without LD                  +/−      ND      ND                       Alive for 12 months without recurrence

  Kadono         45    F     (−)        Normal   Normal    S4               75                    Partial hepatectomy without LD                  +/+      ND      ND                       Alive for 12 months without recurrence

  Ishii          59    M     HBV        53.7     6752      Right lobe       140                   Extended right lobectomy with LD                ND/+     ND      ACT: GEM, cisplatin\     Alive for 4 months with\
                                                                                                                                                                   GEM, S-1                 multiple liver metastasis

  Jung           62    M     Alcohol    2.2      12.1      Right lobe       50                    Right lobectomy without LD                      ND/+     (+)     ND                       ND

  Tomioku        59    F     (−)        Normal   32.1      Right lobe       100                   Extended right lobectomy without LD             +/+      ND      ACT: GEM, S-1\           Alive for 84 months with intrahepatic recurrence
                                                                                                                                                                   Additional hepatectomy   

  Yoh            72    M     HCV        ND       ND        S6/8             50                    Extended right lobectomy without LD             +/+      ND      ND                       Died after 65 days with multiple liver metastases

  Suzumura       45    M     HBV        ND       ND        S7               23                    Posterior segmentectomy without LD              +/+      (−)     ND                       Died after 20 months with lymph node recurrence

  Sakane         56    F     (−)        ND       ND        Right lobe       16                    Partial hepatectomy without LD                  +/+      ND      ND                       ND

  Present case   79    F     (−)        1.6      370       S4               60                    Left lobectomy without LD                       +/+      (+)     ACT: S-1\                Alive for 10 months with multiple liver metastases
                                                                                                                                                                   GEM                      
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: ACT, adjuvant chemotherapy; CA19-9, carbohydrate antigen 19-9; CEA, carcinoembryonic antigen; CK, cytokeratin; EpCAM, epithelial cell adhesion molecules; F, female; GEM, gemcitabine; HBV, hepatitis B virus; HCV, hepatitis C virus; LD, lymph node dissection; M, male; ND, not described.
